- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 265/10 - 1,3-OxazinesHydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
Patent holdings for IPC class C07D 265/10
Total number of patents in this class: 62
10-year publication summary
|
5
|
1
|
3
|
3
|
1
|
2
|
1
|
2
|
1
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Vitae Pharmaceuticals, Inc. | 87 |
8 |
| Boehringer Ingelheim International GmbH | 4494 |
5 |
| Instituto Mexicano Del Petroleo | 208 |
4 |
| Mirati Therapeutics, Inc. | 285 |
4 |
| Wisconsin Alumni Research Foundation | 3915 |
3 |
| Abbvie Inc. | 1837 |
3 |
| Gilead Calistoga LLC | 35 |
3 |
| Pfizer Inc. | 3375 |
2 |
| Nissan Chemical Industries, Ltd. | 1661 |
2 |
| NOVUS International, Inc. | 141 |
2 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2980 |
2 |
| Calico Life Sciences LLC | 106 |
2 |
| BASF SE | 21165 |
1 |
| The Regents of the University of California | 20590 |
1 |
| International Business Machines Corporation | 62325 |
1 |
| Merck Patent GmbH | 5669 |
1 |
| FUJIFILM Corporation | 30327 |
1 |
| Massachusetts Institute of Technology | 10204 |
1 |
| Agios Pharmaceuticals, Inc | 222 |
1 |
| Gilead Sciences, Inc. | 2207 |
1 |
| Other owners | 14 |